Drug Profile
OSU 6162
Alternative Names: Movement disorder therapeutics - Pfizer; OSU6162; PNU-9639; PNU-96391; PNU-96391ALatest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Carlsson Research AB
- Developer Carlsson Research AB; Goteborg University; NeuroSearch; Oslo University Hospital; Pfizer
- Class Antidepressants; Antipsychotics; Piperidines; Small molecules; Sulfones
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bipolar depression; Chronic fatigue syndrome; Depressive disorders; Stroke; Subarachnoid haemorrhage
- Discontinued Parkinson's disease
Most Recent Events
- 21 Apr 2022 Phase-II clinical trials in Depressive disorders (Treatment-resistant, In adults, In the elderly, Adjunctive treatment) in Sweden (PO) (NCT05641623)
- 25 Oct 2021 Phase-II clinical trials in Bipolar depression in Sweden (PO) (NCT05296356)
- 23 Mar 2021 Carlsson Research AB completes a phase I/II trial in Chronic fatigue syndrome in Sweden (PO, Capsule) (EudraCT2011-001650-29)